Giving Life to Science®

Our mission is to discover, develop and commercialize new therapies for devastating diseases, often anchored around orphan conditions, where limited or no treatment options currently exist for patients

Focus on immunological, fibrotic and lymphatic system disorders initially anchored around orphan indications

27 therapeutics and therapeutic candidates

16 are clinical stage

2 granted FDA clearance & European marketing authorization

Relationships with leading pharma companies or their investment arms

Team of world-class scientists and industry leaders

PureTech's Components of Value


Learn more about our unique discovery process

Wholly Owned Pipeline

Our programs*
Phase 1
Phase 2
Phase 3
Idiopathic pulmonary fibrosis (IPF)
Lymphatic flow disorders, including lymphedema
Anti-Galectin-9 MAb
Solid tumors
Anti-Delta-1 MAb
Solid tumors
Oral Allopregnanolone
Neurological and neuropsychological conditions
Oral Immunosuppressant
IBD/chronic pouchitis
Oral IL-22 +
(Partnered program)
Phase completedPhase in progressRegistration-enabling studies to begin in 1H2022

Cash at Parent Level

Founded Entities

Internal Pipeline
PureTech's Lymphatic Leap
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Science: The Gut’s Clostridium Cocktail
Press releases
PureTech Founded Entity Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million
Press releases
Results of Annual General Meeting
Press releases
PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300

1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.
2 Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection, also known as post-acute COVID-19 syndrome (PACS).
3 Funding figure includes private equity financings, loans and promissory notes, public offerings or grant awards. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations. Funding figure does not include Gelesis’ gross proceeds of approximately $105.0 million from its January 2022 SPAC merger.
4 This represents a non-IFRS measure used by management for planning and reporting purposes. Please see below for a reconciliation of this measure to consolidated cash and cash equivalents, which is the most directly comparable measure calculated in accordance with IFRS:

PureTech Level Cash and Cash Equivalents is an alternative performance measure which is adjusted and constitutes a non-IFRS measure. We believe that these non-IFRS performance measures, when provided in combination with IFRS measures, will provide investors, analysts and other stakeholders with helpful complementary information to better understand our financial position from period to period. The measures are not substitutable for IFRS measures and should not be considered superior to measures presented in accordance with IFRS. These figures are unaudited and do not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2021 or March 31, 2022.